The ATTR-CM Toolkit
With the availability of therapies for ATTR-CM, the late-onset (wild type) Transthyretin Amyloidosis can no longer be considered a rare disease. Thus, there is an increasing need to support patients in their disease journey. WHF has developed a new toolkit designed for patients with ATTR-CM that builds on the main gaps in achieving optimal care for patients including disease impact; genetic implications; treatment options; and a new symptom monitor and tracker.
This practical tool helps you stay organized and in control. It includes:
-
Emergency contact and medication lists
-
Symptom and wellness trackers
-
Medication logs
-
Questions for doctor visits
-
A personal journal for reflections and mental well-being
